Prospective study of fertility-sparing treatment with chlormadinone acetate for endometrial carcinoma and atypical hyperplasia in young women.

Autor: Ouasti S; Department of Obstetrics and Gynecologic Surgery, Hôpital Bichat Claude Bernard, Paris, France., Bucau M; Department of Anatomopathology, Hôpital Bichat Claude Bernard, Paris, France., Larouzee E; Department of Obstetrics and Gynecologic Surgery, Hôpital Bichat Claude Bernard, Paris, France., Clement De Givry S; Department of Radiology, Hôpital Bichat Claude Bernard, Paris, France., Chabbert-Buffet N; Department Obstetrics, Gynecology and Reproductive Medicine, APHP Sorbonne University Hôpital Tenon, Paris, France., Koskas M; Department of Obstetrics and Gynecologic Surgery, Hôpital Bichat Claude Bernard, Paris, France.
Jazyk: angličtina
Zdroj: International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics [Int J Gynaecol Obstet] 2022 May; Vol. 157 (2), pp. 452-457. Date of Electronic Publication: 2021 Oct 04.
DOI: 10.1002/ijgo.13941
Abstrakt: Objective: To confirm that the efficiency of the use of chlormadinone acetate for 6 months to obtain remission of atypical hyperplasia or endometrial carcinoma is comparable to that of the use of other fertility-sparing treatments.
Method: The present study is based on the PREFERE prospective registry. All the patients received 3 or 6 months of chlormadinone acetate and were evaluated by hysteroscopic resection and pipelle sampling every 3 months.
Results: Ninety-four patients were included. Seventy-nine patients achieved complete remission at 6 months (84%). No patients stopped treatment because of a lack of tolerance. Twenty-four per cent of the patients achieved a live birth.
Conclusion: Chlormadinone acetate is an effective and well-tolerated fertility-sparing treatment. Its benefits over other progestins are its tolerability, and its absence of contraindications, which make it a good choice for patients with thromboembolism and high vascular risk.
(© 2021 International Federation of Gynecology and Obstetrics.)
Databáze: MEDLINE
Externí odkaz: